n-Butyl lactate structure
|
Common Name | n-Butyl lactate | ||
---|---|---|---|---|
CAS Number | 138-22-7 | Molecular Weight | 146.184 | |
Density | 1.0±0.1 g/cm3 | Boiling Point | 189.4±8.0 °C at 760 mmHg | |
Molecular Formula | C7H14O3 | Melting Point | −28 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 69.4±0.0 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Name | Butyl lactate |
---|---|
Synonym | More Synonyms |
Density | 1.0±0.1 g/cm3 |
---|---|
Boiling Point | 189.4±8.0 °C at 760 mmHg |
Melting Point | −28 °C(lit.) |
Molecular Formula | C7H14O3 |
Molecular Weight | 146.184 |
Flash Point | 69.4±0.0 °C |
Exact Mass | 146.094299 |
PSA | 46.53000 |
LogP | 0.88 |
Vapour density | 5.04 (vs air) |
Vapour Pressure | 0.2±0.8 mmHg at 25°C |
Index of Refraction | 1.432 |
Water Solubility | 42 g/L (25 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | Eyeshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter |
Hazard Codes | Xi:Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | S26-S36-S37/39 |
WGK Germany | 2 |
RTECS | OD4025000 |
Packaging Group | I; II; III |
HS Code | 2918110000 |
Precursor 10 | |
---|---|
DownStream 10 | |
HS Code | 2918110000 |
---|---|
Summary | 2918110000. lactic acid, its salts and esters. VAT:17.0%. Tax rebate rate:13.0%. Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward). MFN tariff:6.5%. General tariff:30.0% |
An insight on human skin penetration of diflunisal: lipogel versus hydrogel microemulsion.
Drug Dev. Ind. Pharm. 41(1) , 141-7, (2014) Diflunisal is a NSAID used in acute and long term management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis and symptoms of primary dysmenorrhea. However, its oral use i... |
|
Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication.
Int. J. Nanomedicine 10 , 4459-78, (2015) In this study, an optimized nanodispersible oral dosage form (containing a lactate ester) was developed for cilostazol (CZL). CZL is a phosphodiesterase inhibitor used for intermittent claudication. W... |
|
Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique.
Int. J. Pharm. 257(1-2) , 153-60, (2003) A preparation method for nanoparticles based on the emulsification of a butyl lactate or benzyl alcohol solution of a solid lipid in an aqueous solution of different emulsifiers, followed by dilution ... |
Propanoic acid, 2-hydroxy-, butyl ester |
UNII:0UI63W814U |
MFCD00004519 |
n-Butyl lactate |
Lactic Acid Butyl Ester |
Butyl 2-hydroxypropanoate |
EINECS 205-316-4 |
Butyl 2-Hydroxypropionate |
Butyl Lactate |